- Healthcare Professionals
- About us
- Clinician leads & governance
Clinical governance
Through regulation and governance, we deliver the latest evidence-based treatments in a safe and high-quality environment.
Governance
At GenesisCare, through regulation and governance, we deliver the latest evidence- based treatments in a safe and high-quality environment.
Our Clinical Governance Committee sets safe and effective treatment protocols, reviews pathways, manages risk and works with the CQC. All consultant practising privileges are reviewed and continuously validated by our Medical Advisory Committee. Cases outside standard protocol are referred to our Clinical Advisory Team to peer review and recommend the best treatment plan.
Our Clinical Leaders Forum consists of leading practitioners in all fields of oncology working with GenesisCare to spearhead best practice and innovations, and expand our referral network.
Our Clinical Reference Groups specialising in breast, prostate, SABR and haematology oversee the continuous process of clinical evaluation, using peer-group collaboration and data-driven insights to design and implement standardised treatment protocols across our centres.
SABR Reference Group
Delivering clinical excellence
We are committed to an environment of clinical excellence, objectivity and accountability. Our SABR service is spearheaded by the SABR Reference Group – an advisory team of leading NHS clinicians who have been recruited due to their clinical expertise, each with a high volume of SABR cases performed, in order to form the UK’s leading SABR consortium.
The role of the SABR Reference Group is to provide the necessary clinical oversight for a safe and effective SABR service across the GenesisCare network. This includes improved access to SABR treatments, introducing new clinicians to the SABR network, overseeing training and competency frameworks and contributing to the evidence base. In addition, they drive the implementation of existing and emerging radiation technologies, in particular the MRIdian for MR-guided SABR, with responsibility for the treatment network as well as academic collaboration with the University of Oxford.
Group members also comprise the SABR Advisory Team (SAT) who lead the multidisciplinary teams and assess all referrals through the eMDT.
SABR Reference Group
Dr James Good
Clinical oncologist
MSc PhD FRCR
Special interest: Treatment of cancers of the head & neck, bowel and rectum using chemotherapy, radiotherapy, targeted therapy, and immunotherapy
Clinical oncologist
MBBS, MRCP, FRCR
Special interest: Respiratory motion management and advanced technical radiotherapy
Clinical oncologist
BSc, MB BS, MRCP, FRCR, MD
Special interest: Areas of functional cancer imaging, and combining immunotherapy with radiation treatment.
Clinical oncologist
MA, BM BCh, MD, MRCP, FRCR
Special interest: Prostate cancer, bladder cancer, lung cancer, radiotherapy, stereotactic ablative body radiotherapy (SABR), chemotherapy, targeted therapies, and immunotherapy
Consultant Clinical Oncologist
BMedSci, MBChB, MRCP (UK), FRCR, MSc, MD(res)
Special interest: Breast cancer, lung cancer, radiotherapy, chemotherapy, Hormone therapy (endocrine therapy), Targeted therapy, Stereotactic Ablative Radiotherapy (SABR), Intraoperative Radiotherapy (IORT)
Dr Kevin Franks
Dr Crispin Hiley
Associate Professor and Consultant Clinical Oncologist
BSc (HONS.) MBChB (HONS.) PGDIP PHD MRCP FRCR
Special interest: Lung cancer, Role of radiotherapy in mesothelioma, Immunotherapy for non-small cell lung cancer, SABR for oligometastatic disease, Understanding resistance to radiotherapy and immunotherapy in NSCLC, proton therapy
Dr Kasia Owczarczyk
Clinical Oncologist
MBBS, MD (res), USLME, MRCP, FRCR (examination)
Special interest: Gastro-oesophageal cancer, rectal cancer, pancreatic cancer, stereotactic body radiotherapy (SBRT) including MRI guided SBRT, Intraluminal HDR brachytherapy of oesophageal cancer, predictive markers, radiomics
Dr Peter Dickinson
Urology SABR Advisory Team
The Urology SABR Advisory Team is comprised of leading oncologists specialising in urology and is responsible for reviewing all referrals to the GenesisCare SABR service for urological cancers, including kidney and prostate.
Urology SABR Advisory Team
Clinical oncologist
MD, MRCP, FRCR
Special interest: Urology, prostate disease & cancer, testicular, bladder, urological oncology, bone therapy, hormone therapy and chemotherapy
Dr Nicola Dallas
Clinical oncologist
MBChB, MRCP, FRCR
Special interest: Uro-oncology (prostate, bladder, kidney), germ cell tumours (testicular), head and neck and thyroid cancer
Dr Prantik Das
Clinical oncologist
MBBS, MRCP, FRCR
Special interest: Prostate, bladder, kidney, penis, testis, testicular, stomach, neuroendocrine & urological cancers
Dr Dan Ford
Clinical oncologist
MBChB (Hons), BSc, MRCP, FRCR
Special interest: Prostate disease (including prostate cancer), urological oncology, bladder cancer, kidney (renal) cancer, chemotherapy, radiotherapy and paediatric oncology
Dr Carla Perna
Clinical oncologist
MBBS, FRCR (equiv.)
Special interest: Prostate cancer, brachytherapy and testicular cancer, systemic treatment including immunotherapy for prostate cancer and Theranostics
Urology Reference Group
Committed to clinical excellence
We are committed to an environment of clinical excellence, objectivity and accountability. Our prostate service is led by our Urology Reference Group – an advisory team of leading NHS clinicians who have been recruited due to their clinical expertise and experience in the techniques offered in the GenesisCare pathway. The role of the Urology Reference Group is to provide the necessary clinical oversight for a safe and effective uro-oncology service across the GenesisCare network from rapid access diagnostic clinics, through to advanced radiotherapy treatments and Theranostics.
This includes improved access to treatment, introducing new clinicians to the network, overseeing training and competency frameworks and contributing to the evidence base. They also implement a quality framework and measurement for VMAT radiotherapy and spacers.
In addition, they drive the implementation of existing and emerging radiation technologies, in particular the MRIdian for treatment of prostate cancer, as well as academic collaboration with the University of Oxford.
Urology Reference Group
Dr Philip Camilleri
Clinical oncologist
MD, MRCP, FRCR
Special interest: Urology, prostate disease & cancer, testicular, bladder, urological oncology, bone therapy, hormone therapy and chemotherapy
Mr Philip Charlesworth
Consultant Urological Surgeon
BM DM FRCS (Urol.)
Special interest: minimally invasive surgery and open surgery for major urological cancers and subsequent surgical reconstruction
Dr Nicola Dallas
Clinical oncologist
MBChB, MRCP, FRCR
Special interest: Uro-oncology (prostate, bladder, kidney), germ cell tumours (testicular), head and neck and thyroid cancer
Dr Prantik Das
Clinical oncologist
MBBS, MRCP, FRCR
Special interest: Prostate, bladder, kidney, penis, testis, testicular, stomach, neuroendocrine & urological cancers
Clinical oncologist
MBChB (Hons), BSc, MRCP, FRCR
Special interest: Prostate disease (including prostate cancer), urological oncology, bladder cancer, kidney (renal) cancer, chemotherapy, radiotherapy and paediatric oncology
Dr Ruth McPherson
Radiologist
Special interest: PET-CT and urological cancers
Dr Dr Yae-eun Suh
Dr Carla Perna
Clinical oncologist
MBBS, FRCR (equiv.)
Special interest: Prostate cancer, brachytherapy and testicular cancer, systemic treatment including immunotherapy for prostate cancer and Theranostics
Breast Reference Group
The Breast Clinical Reference Group has been formed to support delivery of the Breast Service of Future strategy that was launched in November 2018. The roles of the group include introduction of new protocols and clinical trials, development of the eMDT platform and our genetic pathways, definition and collection of PROMs for all breast cancer patients, launching and promoting One Stop Breast Clinics.
Breast Reference Group
Dr Russell Burcombe
Clinical director and oncologist
MB BS, BSc, MD, FRCP, FRCR
Special interest: Breast and lung cancers and preoperative chemotherapy for breast cancer
Professor P.G. Roy
Consultant oncoplastic breast surgeon
MBBS, MS, MD, FRCS
Special interest: Diagnosis and management of breast diseases, both benign and malignant
Miss Harleen Deol
Consultant oncoplastic breast surgeon
MBBS, MRCS, MSc, DiplC, FRCS (Gen Sur)
Special interest: Breast cancer, benign breast disease, family history risk management, oncoplastic and reconstructive breast surgery, cosmetic breast surgery
Dr Fleur Kilburn-Toppin
Specialist advisor breast radiology
BA (Hons), MA, MB BChir, FRCR
Special interest: Breast screening and personalised imaging surveillance for patients
Dr Sileida Oliveros
Clinical oncologist
MBBS, MRCP (UK), FRCR, MD
Special interest: Genetic and genomic pathways, breast cancer and head and neck cancer
Neuro-oncology Reference Group
A focus on clinical excellence to deliver neuro-oncology services
We are committed to creating an environment of clinical excellence for SRS and neuro-oncology services. Our protocols are adapted from international best practice and overseen by a core team of specialists selected on the basis of their extensive experience and high-quality credentials. Their key role is to align the neuro-clinical service with evidence-based treatments such as SRS to ensure safe, consistent care across all of our centres. This robust forum guides all aspects of clinical governance, patient selection, peer review, education, research and assessment of new clinicians to the neuro-oncology team.
In particular, the Clinical Reference Group form the backbone of our eMDT system – a multidisciplinary team-working platform that connects our experts with a wider group of referring clinicians to discuss and review patient care.
Clinical Reference Group
The Clinical Reference Group take carriage of crafting a clinical strategy that encompasses widening access, improving quality and delivery efficiency. Their key role is to align the neuro-clinical service with evidence-based treatments such as SRS to ensure safe and consistent care.
Neuro-oncology Reference Group
Dr Anup Vinayan
Clinical oncologist
MBBS, MRCP, FRCR ,Pgdip
Special interest: Stereotactic radiosurgery such as Cyberknife and Gamma knife (primary brain, brain metastases and central nervous system)
Professor Puneet Plaha
Neurosurgeon
MB BS, MS, MD, FRCS (SN)
Special interest: Endoscopic minimally invasive brain tumour surgery and awake surgery
Dr Luis Aznar-Garcia
Consultant clinical oncologist
MD, PhD, MRCR
Special interest: Hepato-pancreato-biliary, breast cancers, SBRT and stereotactic radiosurgery (brain metastases, benign tumours and spine)
Consultant neurosurgeon
MB BS BSc FRCS FRCS (neurosurg)
Special interest: Tumours of the central nervous system, spinal degenerative disease and hydrocephalus and stereotactic radiosurgery on the Gamma knife
Dr Alison Falconer
Clinical oncologist
Special interest: Uro-oncology, prostate cancer, bladder cancer, neuro-oncology, treatment of pituitary tumours
Dr Chris Herbet
Consultant Clinical Oncologist
BSc MBChB MRCP FRCR
Special interest: Brain cancer, skin cancer, spine cancer
Neuro-oncology MDT
The Breast Clinical Reference Group has been formed to support delivery of the Breast Service of Future strategy that was launched in November 2018. The roles of the group include introduction of new protocols and clinical trials, development of the eMDT platform and our genetic pathways, definition and collection of PROMs for all breast cancer patients, launching and promoting One Stop Breast Clinics.
Neuro-oncology MDT
Mr Richard Stacey
Neurosurgeon
MBBS (London) FRCS, FRCS (surg. neurology)
Special interest: Intracranial, spinal, neuro-oncology and epilepsy
Dr Luis Aznar-Garcia
Consultant clinical oncologist
MD, PhD, MRCR
Special interest: Hepato-pancreato-biliary, breast cancers, SBRT and stereotactic radiosurgery (brain metastases, benign tumours and spine)
Dr Meera Nandhabalan
Clinical oncologist
BM BCh BA FRCR PhD
Special interest: stereotactic radiotherapy (gliomas and benign tumours), targeted therapies, immunotherapies as well as chemotherapy and complex radiotherapy
Mr David Peterson
Consultant neurosurgeon
MB BS BSc FRCS FRCS (neurosurg)
Special interest: Tumours of the central nervous system, spinal degenerative disease and hydrocephalus and stereotactic radiosurgery on the Gamma knife
Professor Puneet Plaha
Neurosurgeon
MB BS, MS, MD, FRCS (SN)
Special interest: Endoscopic minimally invasive brain tumour surgery and awake surgery
Dr Pieter Pretorius
Neuroradiologist
MBChB (University of the Free State) MSc (OXON) FRCR
Special interest: Diagnostic imaging of conditions of the central nervous system, spine, head and neck region including ENT and orbital conditions
Dr Fintan Sheerin
Neuroradiologist
MA hons Cantab Physiology MB, Bchir hons Cantab MRCP UK FRCR
Special interest: Diagnostic imaging of conditions of the central nervous system, spine, head and neck region
Dr Anup Vinayan
Clinical oncologist
MBBS, MRCP, FRCR ,Pgdip
Special interest: Stereotactic radiosurgery such as Cyberknife and Gamma knife (primary brain, brain metastases and central nervous system)
Dr Natalie Voets
Neuroimaging
PhD
Special interest: Neuroimaging (MRI, Functional MRI, Tractography)
Professor Hany Eldeeb
Clinical oncologist
MBBch, MSc, MD, CCST, FRCR
Special interest: Oncology, breast, brain and prostate cancers, central nervous system tumours, using chemotherapy, radiotherapy, monoclonal antibodies and hormonal treatment
Head and neck service MDT
Our head and neck service has been designed with leading head and neck experts to provide speed of access and ease-of-referral to comprehensive diagnostics and world-class treatment within our specialist private oncology centres.
Head and neck service MDT
Professor Stuart Winter
Consultant ENT, head and neck surgeon
MD MB ChB BSc FRCS(ORL-HNS)
Special interest: Lumps in the neck, cancer of the head and neck, salivary gland problems, swallowing problems, voice and sinus problems
Mr Priy Silva
Consultant ENT, head and neck surgeon
FRCS, MD, MB CHB
Special interest: ENT, benign and malignant head and neck problems
Mr Satheesh Prabhu
Consultant oral and maxillofacial surgeon
BDS, FDSRCS, MBChB, MRCS, FRCS (OMFS)
Special interest: Head and neck cancer, oral rehabilitation including dental/facial implants, Zygoma implants and salivary gland disease
Dr Sileida Oliveros
Clinical oncologist
MBBS, MRCP (UK), FRCR, MD
Special interest: Genetic and genomic pathways, breast cancer and head and neck cancer
Dr Ketan Shah
Clinical oncologist
BM, BCh, MA (Cantab), BMChB (Oxon), MRCP, PGDip Oncology, FRCR, DPhil Radiobiology (Oxon)
Special interest: Breast cancer and head and neck cancer
Dr Nicola Dallas
Clinical oncologist
MBChB, MRCP, FRCR
Special interest: Uro-oncology (prostate, bladder, kidney), germ cell tumours (testicular), head and neck and thyroid cancer
Dr Fintan Sheerin
Neuroradiologist
MA hons Cantab Physiology MB, Bchir hons Cantab MRCP UK FRCR
Special interest: Diagnostic imaging of conditions of the central nervous system, spine, head and neck region
National lung cancer MDT
The GenesisCare National Lung Cancer MDT brings together specialists from oncology, radiology, surgery, and other key disciplines to develop personalised treatment plans.
By leveraging diverse expertise and evidence-based approaches, the MDT meetings will ensure each patient receives the most accurate diagnosis and tailored treatment pathway, to improve outcomes and quality of life.
Meet our MDT members:
Dr Crispin Hiley
Consultant Clinical Oncologist and Associate professor
BSc (HONS.) MBChB (HONS.) PGDIP PHD MRCP FRCR
Special interests: Lung cancer, mesothelioma, stereotactic radiotherapy for patients with metastatic disease.
Dr Alastair Moore
Consultant Respiratory Physician
MBBS, FRCP, PhD, RCPathME
Special interest: Lung cancer
Dr Riyaz Shah
Consultant Medical Oncologist
MB, BS, FRCP, PhD
Special interests: Lung cancer, mesothelioma
Mr Richard Milton
Consultant Thoracic Surgeon
MB ChB, FRCS(CTh), FRCSEd
Special interest: Thoracic cancers
Dr Mark Duncan
Consultant Thoracic Radiologist
Special interest: Thoracic radiology
Dr Fiona Macleod
Consultant Thoracic Radiologist
Special interest: Cardiothoracic radiology
GenesisCare is uniquely placed with 14 specialist outpatient centres across the UK, providing patients with access to world-class cancer care and state-of-the-art, treatments, facilities and services which include:
- Stereotactic ablative radiotherapy (SABR), including complex SABR and the UK’s first two MRIdian MR linacs for MR-guided radiotherapy at our centres in Oxford and Cromwell Hospital London
- Comprehensive systemic anti-cancer therapies (SACTs) with dedicated clinical nurse specialists and private chemotherapy suites
- Compassionate chemotherapy nurses available 24/7 by telephone providing patients with advice and support
- Integrative cancer care including wellbeing therapies and exercise medicine
Purpose
The purpose of the GenesisCare National Lung Cancer MDT is to provide a multidisciplinary review and advisory forum which makes recommendations for patient care and treatment approaches. This includes but is not limited to:
- Diagnostic investigations required, including interventional percutaneous or bronchoscopic biopsies
- Recommendations on appropriate pathology and molecular diagnostics
- Systemic therapy in the neo-adjuvant, adjuvant, and metastatic setting
- Management of systemic therapy toxicity including immune related adverse effects
- Conventional and stereotactic radiotherapy for both intracranial and extracranial sites
For treatment at GenesisCare UK, patients with oligometastatic extracranial disease would need to be presented at the National GenesisCare SABR MDT if recommended, and SRS cases require secondary review at the National GenesisCare Neuro-oncology MDT. Referrers will be supported to access care at a GenesisCare UK centre for their patients, but treatment at a GenesisCare centre is not a pre-requisite to access the GenesisCare National Lung Cancer MDT.
Frequency of meetings
The MDT members will review submitted cases weekly on a Thursday evening via an asynchronous electronic MDT. Clinicians referring patients to the MDT may also discuss the case directly with the MDT members prior to the formal MDT meeting taking place.
The submission deadline for cases to be discussed at the MDT is Tuesday at midday. This allows enough time for all information to be collated and uploaded into our Context Health eMDT platform by our GenesisCare National Lung Cancer MDT coordinator.
If you would like a case discussing at the MDT, a completed National Lung Cancer MDT proforma should be submitted to our Lung MDT Coordinator, Serena Thomas at lung@genesiscare.co.uk along with the minimum data set which must include the following:
- Referring clinician’s clinic letter listing any prior treatment or relevant co-morbidities
- All previous and most recent imaging and radiology reports
- Pulmonary function test results if available e.g. FEV1 and TLC
- Histopathology report for patients who have a confirmed diagnosis of cancer
- Molecular diagnostic reports (e.g. next generation sequencing)
Once the case has been discussed at the MDT and the recommendation has been agreed, the MDT platform will generate an outcome report which will be distributed back to you. This outcome report will support you and your patients to secure insurer pre-authorisation where appropriate.
If you would like more information about how to access the GenesisCare National Lung Cancer MDT for your patients, please contact: lung@genesiscare.co.uk